Alzheimer’s Disease (AD) Report Overview
In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact cause of AD is not fully understood, scientists evaluated that in most cases the disease is caused by a combination of genetic, lifestyle, and environmental factors that affect the brain over time. Recent research studies and clinical trials are focused on the role of two proteins, beta-amyloid and tau proteins, to identify disease etiology.
Alzheimer’s Disease (AD) Market Outlook, 2023-2033 (Total Prevalent Cases)
Buy the Full Report for More Insights into the Alzheimer’s Disease (AD) Market Forecast
The AD market research report provides an overview of the risk factors and the global and historical epidemiological trends impacting the disease in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). Additionally, this report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AD by DSM-IV criteria. The total prevalent cases and the diagnosed prevalent cases of AD are segmented by age (65–69 years, 70–79 years, and 80 years and older) and sex.
| Market Size (2023) | 15,987,619 Cases |
| AGR (2023-2033) | >4% |
| Forecast Period | 2023-2033 |
| Key Countries | · The US
· France · Germany · Spain · Italy · The UK · Japan · China |
| Key Sex Segments | · Men
· Women |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Alzheimer’s Disease (AD) Market Segmentation by Country
The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, Japan, and China. In 2023, the US accounted for the highest percentage of total prevalent cases of AD in the 8MM. Any change in the total prevalent cases of AD by DSM-IV criteria is attributable to changing population demographics in the 8MM.
` Alzheimer’s Disease (AD) Market Analysis by Country, 2023 (%)
Buy the Full Report for More Country Insights into the Alzheimer’s Disease (AD) Market
Download a Free Report Sample
Alzheimer’s Disease (AD) Market Segmentation by Sex
Based on sex, the market can be segmented into men and women. In 2023, the total prevalent cases of Alzheimer’s disease (AD) in the 8MM were higher in women than men. Among the 8MM, Italy had the largest differences in the total prevalent cases of Alzheimer’s disease (AD) in men and women.
Alzheimer’s Disease (AD) Market Analysis by Sex, 2023 (%)
Buy the Full Report for More Sex Insights into the Alzheimer’s Disease (AD) Market
Segments Covered in the Report
Alzheimer’s Disease (AD) Market Country Outlook (Total Prevalent Cases)
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
- China
Alzheimer’s Disease (AD) Market Sex Outlook (Total Prevalent Cases)
- Men
- Women
Scope of Report
- The report also includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of MCI segmented by age (65–69 years, 70–79 years, and 80 years and older) and sex.
- The report provides a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of pre-clinical (pre-symptomatic) AD segmented by age (55–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.
- The report also includes the total prevalent cases and diagnosed prevalent cases of AD by severity. Although not covered in this report, total prevalent cases and diagnosed prevalent cases of EOAD can be found in the model.
- This epidemiology forecast for AD is supported by data obtained from peer-reviewed articles and population-based studies. GlobalData epidemiologists applied the DSM-IV criteria to diagnose AD patients across the 8MM. Accordingly, the total prevalent cases and diagnosed prevalent cases of AD in the 8MM are based on the latest data available by DSM-IV criteria. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast total prevalent cases and the diagnosed prevalent cases of AD across these markets.
Reasons to buy
The Alzheimer’s disease (AD) epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AD therapeutics in each of the markets covered.
Table of Contents
Tables
Table 1: Summary of newly added data types
Table 2: Summary of updated data types
Table 3: Risk factors and comorbidities for AD
Graphs
Figure 1: 8MM, total prevalent cases of AD by DSM-IV criteria, both sexes, N, ages ≥65 years, 2023 and 2033
Figure 2: 8MM, total prevalent cases of pre-clinical (pre-symptomatic) AD, both sexes, N, ages ≥55 years, 2023 and 2033
Figure 3: 8MM, total prevalent cases of MCI, both sexes, N, ages ≥65 years, 2023 and 2033
Figure 4: 8MM, total prevalence of AD by DSM-IV criteria (%), men and women, ages ≥65 years, 2023
Figure 5: 8MM, total prevalence of pre-clinical (pre-symptomatic) AD (%), men and women, ages ≥55 years, 2023
Figure 6: 8MM, total prevalence of MCI (%), men and women, ages ≥65 years, 2023
Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD by DSM-IV criteria
Figure 8: 8MM, sources used to forecast the total prevalent cases of AD by severity
Figure 9: 8MM, sources used to forecast the total prevalent cases of pre-clinical (pre-symptomatic) AD
Figure 10: 8MM, sources used to forecast the total prevalent cases of MCI
Figure 11: 8MM, total prevalent cases of AD by DSM-IV criteria, N, both sexes, ages ≥65 years, 2023
Figure 12: 8MM, total prevalent cases of AD by DSM-IV criteria by age, N, both sexes, 2023
Figure 13: 8MM, total prevalent cases of AD by DSM-IV criteria by sex, N, ages ≥65 years, 2023
Figure 14: 8MM, total prevalent cases of AD by severity, N, both sexes, ages ≥65 years, 2023
Figure 15: 8MM, total prevalent cases of pre-clinical (pre-symptomatic) AD, N, both sexes, ages ≥55 years, 2023
Figure 16: 8MM, total prevalent cases of pre-clinical (pre-symptomatic) AD by age, N, both sexes, 2023
Figure 17: 8MM, total prevalent cases of pre-clinical (pre-symptomatic) AD by sex, N, ages ≥55 years, 2023
Figure 18: 8MM, total prevalent cases of MCI, N, both sexes, ages ≥65 years, 2023
Figure 19: 8MM, total prevalent cases of MCI by age, N, both sexes, 2023
Figure 20: 8MM, total prevalent cases of MCI by sex, N, ages ≥65 years, 2023












